150 related articles for article (PubMed ID: 22065362)
1. Canada's laws on pharmaceutical intellectual property: the case for fundamental reform.
Grootendorst P; Bouchard R; Hollis A
CMAJ; 2012 Mar; 184(5):543-9. PubMed ID: 22065362
[No Abstract] [Full Text] [Related]
2. The ongoing regulation of generic drugs.
Frank RG
N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
[No Abstract] [Full Text] [Related]
3. Intellectual property rights and the Canadian pharmaceutical marketplace: where do we go from here?
Lexchin J
Int J Health Serv; 2005; 35(2):237-56. PubMed ID: 15932005
[TBL] [Abstract][Full Text] [Related]
4. Limiting "evergreening" for a better balance of drug innovation incentives.
Stanbrook MB
CMAJ; 2013 Aug; 185(11):939. PubMed ID: 23877665
[No Abstract] [Full Text] [Related]
5. Intellectual property. Balancing innovation and access: patent challenges tip the scales.
Higgins MJ; Graham SJ
Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944
[No Abstract] [Full Text] [Related]
6. Health policy or intellectual property policy? The fight over Bill C-91. Canadian Healthcare Association.
Int J Health Care Qual Assur Inc Leadersh Health Serv; 1997; 10(2-3):vii-x. PubMed ID: 10169229
[TBL] [Abstract][Full Text] [Related]
7. On access and accountability--two Supreme Court rulings on generic drugs.
Boumil MM; Curfman GD
N Engl J Med; 2013 Aug; 369(8):696-7. PubMed ID: 23923990
[No Abstract] [Full Text] [Related]
8. Intellectual property. Challenges to India's pharmaceutical patent laws.
Sampat BN; Shadlen KC; Amin TM
Science; 2012 Jul; 337(6093):414-5. PubMed ID: 22767892
[No Abstract] [Full Text] [Related]
9. Understanding the Rewards of Successful Drug Development - Thinking Inside the Box.
Khullar D; Ohn JA; Trusheim M; Bach PB
N Engl J Med; 2020 Jan; 382(5):473-480. PubMed ID: 31995697
[No Abstract] [Full Text] [Related]
10. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
McPhie DC
Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
[No Abstract] [Full Text] [Related]
11. Staving off death: a case study of the pharmaceutical industry's strategies to protect blockbuster franchises.
Gorlin DI
Food Drug Law J; 2008; 63(4):823-64. PubMed ID: 19601385
[No Abstract] [Full Text] [Related]
12. Reforming Canada's Access to Medicines Regime.
Esmail LC
CMAJ; 2007 Jul; 177(3):270. PubMed ID: 17664454
[No Abstract] [Full Text] [Related]
13. Reforming Canada's Access to Medicines Regime.
Elliott R
CMAJ; 2007 Jul; 177(3):270-1. PubMed ID: 17664453
[No Abstract] [Full Text] [Related]
14. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
Wang Z
Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
[No Abstract] [Full Text] [Related]
15. Branded drug reformulation: the next brand vs. generic antitrust battleground.
Amoresano GV
Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
[No Abstract] [Full Text] [Related]
16. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
McCabe AR
Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
[No Abstract] [Full Text] [Related]
17. Realizing two-tiered innovation policy through drug regulation.
Ridgway WE
Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
[No Abstract] [Full Text] [Related]
18. Bill C-30: who wins and who loses in Canada's pharmaceutical patent battles?
Hollis A
Expert Opin Ther Pat; 2018 Jan; 28(1):1-3. PubMed ID: 28974123
[No Abstract] [Full Text] [Related]
19. Canada's Patented Medicines (Notice of Compliance) Proceedings and Intellectual Property.
Bian H; McCourt C
Cold Spring Harb Perspect Med; 2015 Jan; 5(6):. PubMed ID: 25573772
[TBL] [Abstract][Full Text] [Related]
20. Patents: a threat to innovation?
Manocaran M
Science; 2010 Jan; 327(5961):31-2; author reply 32. PubMed ID: 20044557
[No Abstract] [Full Text] [Related]
[Next] [New Search]
